Up 118%: Is this 'high quality' stock the best-kept secret on the ASX 200?

Why are these pharmaceutical shares turning heads at the moment? The Elvest team explains.

| More on:
Businesswoman whispering in male colleague's ear as he looks surprised

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There is one S&P/ASX 200 Index (ASX: XJO) stock that's going absolutely gangbusters but is hardly spoken about.

Believe it or not, the Neuren Pharmaceuticals Ltd (ASX: NEU) share price has gained 118% in the past year.

Just in the past six weeks the healthcare stock has rocketed more than 53%.

The analysts at the Elvest Fund are fans, and explained what's going on.

"Neuren Pharmaceuticals, a leading pharmaceutical company focused on neurodevelopmental disorders, rallied following the release of better than expected quarterly sales results," read their memo to clients.

"Neuren receives royalty and milestone payments from Nasdaq-listed Acadia Pharmaceuticals Inc (NASDAQ: ACAD) on its Daybue product, the world's first and only approved therapy for Rett Syndrome."

But after such a fruitful year, is there much more to come for investors who buy now?

Cash reserves, royalty income, development work

The Elvest team is backing Neuren and its pipeline for further gains.

"The company is currently conducting phase 2 trials of its second drug candidate, NNZ-2591, for a range of disorders," read the memo.

"Phase 2 top-line results are due in December 2023 for the first of these, Phelan McDermid syndrome (PMS)."

While many early stage pharmaceutical and biotechnology companies burn cash like there's no tomorrow, the analysts like that this ASX 200 company has both an income stream and development work.

"With cash reserves of $230 million, a steady stream of high margin royalty income and a promising pipeline of 'orphan drug' designated therapies, Neuren is swiftly emerging as a high quality ASX-listed pharmaceutical.

"Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases."

Last month Bell Potter also expressed its bullishness for Neuren Pharmaceuticals because of the cash cow that is Daybue.

"Daybue's implied 4Q23 annualised sales is US$336 million at the guidance midpoint, which all but guarantees NEU will receive the first US$50m sales milestone in CY24.

"We forecast CY24e DAYBUE sales of ~US$460 million which would result in Neuren receiving US$50 million in royalties plus the US$50 million sales milestone."

All five analysts surveyed on CMC Invest currently rate Neuren Pharmaceuticals shares as a buy.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

People sit in rollercoaster seats with expressions of fear, terror and exhilaration as it goes into a steep downward descent representing the Novonix share price in FY22
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the trading week this Friday.

Read more »

Siblings jumping on a trampoline.
Share Gainers

These 3 ASX 200 stocks are charging higher this week. Own any?

Investors have been piling into these ASX 200 stocks this week. But why?

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Domino's, Nick Scali, REA, and Sigma shares are charging higher today

These shares are ending the week on a high. Let's see why investors are bidding them higher today.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why BWP, Magellan, News Corp, and Winsome shares are pushing higher today

These shares are having a better day than most on Thursday. But why?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was back in form this hump day...

Read more »

A boy stands firm on a rocky cliff holding a rocket in each hand and looking up toward the sky, anticipating flying into space.
Resources Shares

Up 864% in a year, how this ASX mining stock is primed to keep rocketing in 2025

The ASX mining stock looks to be in a sweet spot amid export bans from China and Russia.

Read more »

Happy coal miner.
Energy Shares

Why are ASX coal shares having such a cracking run today?

The latest salvo in the new American tariff war is benefiting some ASX shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Share Gainers

Why BWP, Insignia, Nufarm, and Pinnacle shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »